We have established a pseudotype neutralisation assay for SARS-CoV-2 using similar technologies to what we used previously for SARS and MERS. This has been employed in a consortium effort to study the seroprevalence of COVID-19 antibodies in blood donors. The article can be found here.
Pseudotype virus R&D